Date:3/1/2010

ements relating to the proposed use of proceeds, of the private placement, increase in shareholder value, access to investment capital, and the growth of WorldHeart's overall business,  as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; risks involved in the Levacor VAD Bridge-to-Transplant (BTT) clinical study; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009.

www.worldheart.com

    
    
                              WORLD  HEART CORPORATION                        
                       Condensed Consolidated Balance Sheets                  
                              (United States Dollars)                         
                                    (Unaudited)                               
                                
'/>"/>
SOURCE  World Heart Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. NASDAQ Stock Market Confirms WorldHearts Compliance With NASDAQ Listing Rule 5605
2. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
3. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
4. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
5. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
6. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
7. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
8. Questcor Reports Solid Fourth Quarter Results
9. APC Group, Inc. Reports Multi-Year Deal with Medical Device Manufacturer
10. CRF Health Reports Record Growth and Earnings
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results